Specialty Pharmacy

Leading Experts in Specialty Pharmacy M&A


Triangle Healthcare Advisors has more experience and understanding of the Specialty Pharmacy market than any other provider. 

Rob Monahan and Dan Bramuchi led all Specialty Pharmacy acquisitions for Option Care and Walgreens for over a decade. They completed more than 40 specialty pharmacy transactions generating billions of revenue. Select deals include the Joint Venture between Prime Therapeutics and Walgreens, the acquisition of Cystic Fibrosis Foundation Pharmacy from the Cystic Fibrosis Foundation, the acquisition of Specialty Pharmacy operations of Cardinal Health, the acquisition of the Mail, Specialty and Retail Specialty Pharmacy operations of Bioscrip, and the acquisition numerous independent providers. These deals ranged from massive “lick and stick” central fill locations focused on payor relationships and temperature controlled shipments of expensive biotech drugs, to community-based oral solid medication providers treating chronically ill patients where they live. There is a market for all of these business models.

Dave Evans was COO of BioScrip, Inc., a publicly traded Specialty Infusion business. Dave was responsible for the operations of nearly 70 pharmacies which ranged from pure play, URAC Accredited Specialty Pharmacies, Community-based specialty providers focused on oral solid medications to chronically ill populations, to ACHC Accredited Home Infusion locations that also dispensed various specialty drugs. 

Chuck Gaetano, not only owned a specialty pharmacy, but was the leading broker in the Specialty Pharmacy arena. He brokered numerous deals to Option Care alone. One reason that the partners have decided to affiliate is the strong respect that they gained for the others’ skills while working across the table from each other for so many years.

John Canavan has a unique payor focused understanding of Specialty Pharmacy. As a board member, Finance Chair and Chairman of the Board of HealthNow (Blue Cross and Blue Shield of Western New York), John has unique insights into how payors view Specialty Pharmacy and its growing importance in healthcare.

If you have a specialty pharmacy business to sell, choose the experts at Triangle Healthcare Advisors to guide you to an optimal outcome. We literally wrote the book on how to do Specialty Pharmacy deals.

The future is bright for M&A activity with relatively high valuations. Specialty Pharmacies have been consolidating for many years, and demand is strong due to the fantastic growth. Reimbursement continues to trend downwards, and payors continue to restrict provider panels to get a handle on this costly therapeutic area. Manufacturers have a strong desire to have quality pharmacies provide their products to customers in a timely manner. Continued innovation by Biotech companies and the introduction and acceptance of Biosimilars present unique growth and profit opportunities. There are multiple acquirers in the space including affiliates and subsidiaries of the large providers: Walgreens and CVS, large independents like Diplomat and numerous Private Equity platforms. There is intense buying in all segments. Private equity has billions of capital to put to work. Interest rates are historically low and access to financial leverage is high. Companies want to grow their businesses and the fastest way is through acquisition.

If you have a Specialty Pharmacy business to sell, Triangle Healthcare Advisors can provide you with excellent guidance for an optimal outcome. We know Specialty Pharmacy. We have excellent relationships with the leadership at Walgreens, Rite Aid and CVS, as well as across the private equity landscape. Contact robmonahan@trianglehca.com or danbramuchi@trianglehca.com or chuckgaetano@trianglehca.com or daveevans@trianglehca.com to discuss your business.